Navigation Links
Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study
Date:7/14/2009

GOTHENBORG, Sweden, July 14 /PRNewswire/ -- PharmaSurgics AB. successfully completes Phase I clinical study showing their novel candidate drug PXL01 is safe and well tolerated. Initially developed to prevent post-surgical adhesion formation following hand surgery the product combines the pharmacological effect of PXL01 with the physical barrier effect of the vehicle, and has the potential to be the first anti-adhesion drug on the market. 'These results provide the foundation for proceeding to the next phase, proof of concept study in patients,' said Fredrik Sjovall, CEO of PharmaSurgics, adding 'the proof of concept study in patients of flexor tendon repair surgery is scheduled to start in December 2009.'

Post-surgical adhesions are bands of scar tissue connecting anatomic sites in the body that should not normally be connected. These develop after almost every type of surgery and cause symptoms such as restricted joint mobility, chronic pain, intestinal obstruction and re-operative complications. Following flexor tendon repair surgery post-surgical adhesions lead to decreased strength and function of the affected joints, extensive post-operative physiotherapy and extended periods of sick leave.

About PharmaSurgics

PharmaSurgics in Sweden AB is a Gothenburg based biotech company that develops and commercializes a novel treatment for preventing harmful scarring and promoting wound healing after surgery. PharmaSurgics product concept is based on proprietary synthetic peptides which have strong anti-inflammatory and anti-infectious properties. The company was founded in 2005, based on extensive research by Dr. Inger Mattsby- Baltzer and Professor Kjell Olmarker at Sahlgrenska University Hospital, Gothenborg, Sweden. PharmaSurgics is a Karolinska Development portfolio company.

    For further information please contact
    Fredrik Sjovall, CEO of PharmaSurgics
    Ph: +46-31-762-29-01
    Email: fredrik@pharmasurgics.se


'/>"/>
SOURCE PharmaSurgics AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours
2. Novel gene found for dilated cardiomyopathy
3. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
4. Novel method predicts impact of a covert anthrax release
5. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
6. Novel handheld device detects anthrax with outstanding accuracy and reliability
7. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
8. Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia
9. Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
10. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
11. Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
Breaking Biology News(10 mins):